Barboval (capsules)

General characteristics. Structure:

Active ingredients: ethyl ether of α-bromizovalerianovy acid, menthol solution in mentilovy ether of isovaleric acid, phenobarbital;

1 capsule contains: ethyl ether of α-bromizovalerianovy acid – 10 mg, menthol solution in mentilovy ether of isovaleric acid – 46 mg, phenobarbital – 9,8 mg;

excipients: castor oil, lactoses monohydrate (200), cellulose microcrystallic 102, кросповидон, calcium stearate, silicon dioxide colloid anhydrous.

Pharmacological properties:

Somnolent and sedative drugs. The combined drugs of barbiturates. Code of automatic telephone exchange N05C B02.

Barboval - the combined medicine which therapeutic effect is caused by pharmacological properties of the components which are its part.

Ethyl ether of α-bromizovalerianovy acid has the reflex, calming and spasmolytic effect caused by decrease in reflex irritability in the central parts of the nervous system and strengthening of processes of braking in neurons of bark and subcrustal structures of a brain and also decrease of the activity of the central vasomotor centers and local direct spasmolytic action on smooth muscles.

Phenobarbital suppresses the activating influences of the centers of a reticular formation of an average and a myelencephalon on bark of big hemispheres, thereby reducing flows of exciting influences on a cerebral cortex and subcrustal structures. Reduction of the activating influences renders, depending on a dose, the calming, tranquilizing or somnolent effect. Barboval reduces exciting influences on vasomotor centers, coronary and peripheral vessels, reducing the general arterial pressure, eliminating and warning vasospasms, especially cordial.

Validol soothingly influences the central nervous system, slows down a peristaltics of a stomach and intestines, reduces a meteorism, possesses also moderate reflex vasodilating and spasmolytic effect.

Indications to use:

The neurosises which are followed by a hyperexcitability, sleeplessness, hysteria; as a part of complex treatment of easy attacks of stenocardia, arterial hypertension in an initial stage, tachycardia of functional genesis, at spasms of a stomach and intestines, a meteorism.

Route of administration and doses:

Barboval accept inside. Usually adults accept 1-2 capsules 2-3 times a day for 10-15 days. It is better to accept drug in 20-30 minutes prior to food. After a break in 10-15 days the course of treatment can be repeated. The maximum daily dose - 6 capsules.

Features of use:

Use during pregnancy or feeding by a breast. Drug is not appointed to the pregnant women and women nursing.

Ability to influence speed of response at control of motor transport or work with other mechanisms. Persons whose work is connected with special attention should appoint drug with care: to drivers, operators.

Children. There is no experience of use of drug for treatment of children therefore it is not applied in pediatric practice.

Side effects:

Usually drug is transferred well. In some cases drowsiness, nausea, dizziness, delay of a cordial rhythm, decrease in concentration of attention, skin rash, a small tortoiseshell, an itch, an adynamy, arterial hypotension can be observed. These phenomena pass at reduction of a dose. Allergic reactions are extremely seldom possible. At prolonged use emergence of dependence on drug and a bromism is possible.

Interaction with other medicines:

Simultaneous use with neuroleptics, sedative and tranquilizers potentiates, and with stimulators of the central nervous system - weakens action of each component of drug. Barboval containing derivatives of barbituric acid in the structure strengthens action mestnoanesteziruyushchy, anesthetizing, hypotensive and hypnagogues. Alcohol strengthens effects of drug and can increase its toxicity. Availability in Barboval's list of phenobarbital can induce liver enzymes, and it does undesirable its simultaneous use with medicines which are metabolized in a liver (with coumarin derivatives, griseofulvin, glucocorticoids, peroral contraceptives) as their efficiency will decrease as a result of higher metabolic rate. Drug increases toxicity of a methotrexate.

Contraindications:

Drug is not used to the children, pregnant women and women nursing. It is contraindicated at hypersensitivity to any components of drug, at a liver and renal failure, a hepatic porphyria.

Overdose:

At prolonged or frequent use there can be drug cumulation that leads to clinical manifestations of overdose, namely:
to oppression of the central nervous system that is eliminated with use of stimulators of TsNS (caffeine, Cordiaminum, etc.);
to nystagmus, ataxy, lowering of arterial pressure, deviations in a blood count.

Displays of chronic poisoning with bromine are the depression, apathy, rhinitis, conjunctivitis, hemorrhagic diathesis, lacks of coordination of movements. For elimination of the specified manifestations symptomatic therapy is appointed.

Constant prolonged use of drug can cause accustoming, medicinal dependence, an abstinence syndrome, and sudden phase-out – a withdrawal. Prolonged use of drug sometimes is followed by strengthening of psychodynamic activity instead of the expected sedation. Symptomatic treatment.

Storage conditions:

Period of validity. 1 year 6 months. Not to use drug after the termination of the period of validity specified on packaging. To store at a temperature not over 25 ºС. To store in the place, unavailable to children.

Issue conditions:

Without recipe

Packaging:

On 10 capsules in the blister. On 1 or 3 blisters enclosed in a pack.